StockData

Grifols vs Viatris

GRFS and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GRFS and VTRS compare

Viatris grew revenue faster over the last twelve months (4.4% versus 4.3% for Grifols).

Viatris pays a dividend yielding 2.5%; Grifols does not pay one.

Grifols scores higher on the StockData Score (9 against 6 for Viatris), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGRFSVTRS
Size and price
Market cap–$21.9B
Share price$8.10$19.04
Change, 1 year−13.7%85.3%
Change, 5 years−33.7%38.6%
Beta (5Y)0.910.87
Employees1,61330K
StockData Score
Total score9 (better)6
Valuation score02 (better)
Growth score2 (better)1
Performance score4 (better)0
Health score3 (better)1
Dividend score02 (better)
Valuation
P/S–1.5×
EV/EBITDA–12.6×
P/FCF–11.2×
FCF yield–8.9%
Fair value–$20.87
Margin of safety–8.8%
Growth
Revenue growth (TTM)4.3%4.4% (better)
Revenue growth, 5Y average7.1% (better)3.7%
Net income growth (TTM)156%–
EPS growth (TTM)157%–
EPS growth, 5Y average−8.1%–
Profitability
Gross margin38.0% (better)34.8%
Operating margin16.5% (better)−0.59%
Net margin5.3%–
FCF margin10.4%13.3% (better)
Return on equity7.2%–
Return on invested capital14.6%–
Financial health
Debt / equity0.41–
Net debt / EBITDA0.79 (better)4.59
Interest coverage2.0× (better)−0.2×
Current ratio2.51 (better)1.58
Altman Z-score–1.16
Piotroski F-score5–
Dividends and buybacks
Dividend yield–2.5%
Payout ratio31.8%–
Years of dividend growth–0
Buyback yield–1.4%
Shareholder yield–3.9%
Ownership
Held by institutions20.8%91.5%
Held by insiders0.00%0.36%
Insider net buying, 12 months–−$1.1M
Superinvestors holding–3
Short interest, % of float–3.7%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.